NCT00120705

Brief Summary

The purpose of this study is to assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
204

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Nov 2002

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2002

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2003

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

June 30, 2005

Completed
19 days until next milestone

First Posted

Study publicly available on registry

July 19, 2005

Completed
Last Updated

March 25, 2009

Status Verified

March 1, 2009

First QC Date

June 30, 2005

Last Update Submit

March 24, 2009

Conditions

Keywords

anemiadarbepoetin alfaAmgenNon-myeloid Malignancies

Outcome Measures

Primary Outcomes (1)

  • To assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W)

Secondary Outcomes (1)

  • Assess safety profile of subjects treated with darbepoetin alfa

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007 Oct;12(10):1253-63. doi: 10.1634/theoncologist.12-10-1253.

Related Links

MeSH Terms

Conditions

NeoplasmsAnemia

Interventions

Darbepoetin alfa

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

ErythropoietinColony-Stimulating FactorsGlycoproteinsGlycoconjugatesCarbohydratesProteinsAmino Acids, Peptides, and Proteins

Study Officials

  • MD

    Amgen

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 30, 2005

First Posted

July 19, 2005

Study Start

November 1, 2002

Study Completion

September 1, 2003

Last Updated

March 25, 2009

Record last verified: 2009-03